BioRx Offers Vivaglobin® to Patients with Primary Immune Deficiency Disorders
11/13/2007 12:04:18 PM
CINCINNATI--(BUSINESS WIRE)--BioRx, a specialty pharmaceutical company, announces the availability of Vivaglobin® (immune globulin subcutaneous [human]), an immunoglobulin (ig) replacement therapy for treating patients with primary immune deficiency disorder (PIDD). PIDD is a group of usually-genetic disorders that compromise the immune system, leaving people vulnerable to recurrent, life-threatening infections. An estimated 50,000 Americans have PIDD.